Hematologic Oncology | Specialty

Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

January 21st 2021

Prognostic Significance of IDH Mutations in AML

January 21st 2021

FLT3 Testing for Treatment of AML

January 21st 2021

Dr. Hobbs on the Role of Molecular Testing to Determine Resistance in CML

January 19th 2021

Gabriela Hobbs, MD, discusses the role of molecular testing to determine resistance in chronic myeloid leukemia.

Dr. Jabbour on Selecting Ponatinib After Second-Generation TKI Failure in CML

January 19th 2021

Elias Jabbour, MD, discusses selecting ponatinib after failure of a second-generation TKI therapy in chronic myeloid leukemia.

Remaining ECHELON-2 Questions Spark Novel Research Efforts in PTCL

January 19th 2021

Jakub Svoboda, MD, discusses the results of the ECHELON-2 trial and explained where clinical research is headed in peripheral T-cell lymphoma.

FDA Grants Priority Review to Narsoplimab for HSCT-TMA

January 19th 2021

January 19, 2021 — The FDA has granted priority review to the biologics license application for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Pursuing Pairings of Targeted Agents and HMAs in AML

January 19th 2021

Alison R. Sehgal, MD, discusses some of the novel approaches that have been adopted into practice and ongoing research building on the advances that have been made with targeted therapy.

Frontline Treatment Options in Chronic Lymphocytic Leukemia

January 19th 2021

The experts comment on first-line treatment options in patients with chronic lymphocytic leukemia.

Guidelines for Chronic Lymphocytic Leukemia

January 19th 2021

Dr Brown and Dr Ghia discuss the European Society for Medical Oncology [ESMO] and International Workshop on Chronic Lymphocytic Leukemia [iwCLL] recommended guidelines in assessing and treating chronic lymphocytic leukemia.

Treatment Approaches in Mantle Cell Lymphoma

January 19th 2021

Accurately Diagnosing Mantle Cell Lymphoma

January 19th 2021

Capitalizing on Cellular Therapies in Lymphoma and Myeloma

January 18th 2021

In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.

Could Orca-T Unlock New Path of Reduced Mortality, Prevent GVHD Posttransplant?

January 18th 2021

Steven Devine, MD, discusses the non-relapse mortality data with Orca-T and how this technologic approach is changing how providers approach patients with hematologic malignancies following transplant.

Dr. Cortes on the Future of Ponatinib in CML Treatment

January 18th 2021

Jorge E. Cortes, MD, discusses the future of ponatinib in the treatment of patients with chronic myeloid leukemia.

DREAMM-2 Trial Regimen Safety Profile

January 18th 2021

DREAMM-2 Trial Efficacy Data and Recent FDA Approval

January 18th 2021

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

January 18th 2021

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

January 18th 2021

FDA Approves Subcutaneous Daratumumab Plus VCd for Newly Diagnosed Light-Chain Amyloidosis

January 15th 2021

January 15, 2021 - The FDA has approved daratumumab and hyaluronidase-fihj, a subcutaneous formulation of daratumumab, for use in combination with bortezomib, cyclophosphamide, and dexamethasone in the treatment of patients with newly diagnosed light-chain amyloidosis.